Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine.
Head Neck. 2012 Feb;34(2):201-6. doi: 10.1002/hed.21716. Epub 2011 Jun 29.
Parafibromin is a protein encoded by the HRPT2 oncosuppressor gene, and the expression is reported to be decreased or absent in parathyroid carcinomas.
A total of 26 tumor specimens from 18 patients with adenoma and 8 patients with carcinoma were immune-stained with an antibody against parafibromin.
Parafibromin immunostaining showed strong positivity in 17 of 18 adenomas. Negative staining was noted in 3 of 8 carcinomas, and weak positivity was found in 3 of 8 carcinomas. The remaining 2 cases of carcinoma showed strong positivity. The loss of parafibromin expression (negative or weak positivity) demonstrated 94.4% specificity in the diagnosis of parathyroid carcinomas. Relapses or distant metastases of carcinoma occurred only in cases in which there was a loss of parafibromin immunostaining.
Loss of parafibromin immunostating showed promising results in the differential diagnosis of parathyroid carcinoma from adenoma and may also serve as a prognostic marker.
副甲状腺瘤蛋白是由 HRPT2 抑癌基因编码的一种蛋白质,据报道,在甲状旁腺癌中其表达减少或缺失。
用副甲状腺瘤蛋白抗体对 18 例腺瘤患者和 8 例癌患者的 26 个肿瘤标本进行免疫染色。
18 例腺瘤中有 17 例副甲状腺瘤蛋白免疫染色呈强阳性。8 例癌中有 3 例呈阴性染色,3 例呈弱阳性染色。其余 2 例癌呈强阳性。副甲状腺瘤蛋白表达缺失(阴性或弱阳性)在甲状旁腺癌的诊断中具有 94.4%的特异性。只有在副甲状腺瘤蛋白免疫染色缺失的情况下,癌才会出现复发或远处转移。
副甲状腺瘤蛋白免疫染色缺失在甲状旁腺癌与腺瘤的鉴别诊断中显示出良好的结果,也可能作为一个预后标志物。